About Defymed
Defymed is a company based in Strasbourg (France) founded in 2011 by Sigrist Severine. It operates as a B2B. Defymed has raised $3.72 million across 5 funding rounds from investors including European Union, JDRF and Capital Grand Est. Defymed operates in a competitive market with competitors including Sernova, Beta Bionics, Inreda Diabetic, XOStem and Captix, among others.
- Headquarter Strasbourg, France
- Founders Sigrist Severine
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.72 M (USD)
in 5 rounds
-
Latest Funding Round
$762.22 K (USD), Grant
Oct 01, 2017
-
Investors
European Union
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Defymed
Unlock access to complete
Unlock access to complete
Funding Insights of Defymed
Defymed has successfully raised a total of $3.72M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $762.22 thousand completed in October 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Defymed
Defymed has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, JDRF and Capital Grand Est.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment support is provided to businesses in Grand Est region.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Defymed
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Defymed
Investment portfolio details for Defymed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Defymed
Detailed financials for Defymed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Defymed Comparisons
Peer comparison for Defymed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Defymed
Defymed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sernova, Beta Bionics, Inreda Diabetic, XOStem and Captix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative medicine to deliver proteins and hormones for disease treatment
|
|
| Locked | Locked | Locked |
Bionic pancreas system for type 1 diabetes is provided.
|
|
| Locked | Locked | Locked |
Bi-hormonal artificial pancreas is developed for autonomous glucose regulation.
|
|
| Locked | Locked | Locked |
Stem cells and bio-artificial organs are developed for diabetes treatment.
|
|
| Locked | Locked | Locked |
Develops innovative bioartificial pancreas technologies for diabetes treatment.
|
Detailed competitors of Defymed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Defymed
Complete news archive for Defymed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Defymed
Defymed was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Defymed is headquartered in Strasbourg, France. It is registered at Strasbourg, Grand Est, France.
Sigrist Severine is the current CEO of Defymed. They have also founded this company.
Defymed is a funded company, having raised a total of $3.72M across 5 funding rounds to date.
Defymed, established in 2011, excels in providing healthcare solutions, advancing biotech innovations, developing medical devices, and diabetes treatment. Develops innovative bio-artificial pancreas technologies for type 1 diabetes treatment. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
Defymed's top competitors include Sernova, Beta Bionics and Inreda Diabetic.
Defymed has 3 investors. Key investors include European Union, JDRF, and Capital Grand Est.